BridgeBio will present interim Phase 3 FORTIFY trial data on BBP-418 for LGMD2I/R9 at the MDA Conference.
Quiver AI Summary
BridgeBio Pharma, Inc. announced that additional data from the interim analysis of the Phase 3 FORTIFY clinical trial for BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 will be presented at the MDA Clinical and Scientific Conference in Orlando from March 8-11, 2026. The late-breaking oral presentation will be delivered by Dr. Katherine Mathews on March 11, showcasing that the study met its efficacy endpoints. Yale School of Medicine collaborators will also present a related oral discussion and four posters that improve the understanding of BBP-418 and LGMD2I/R9. BridgeBio aims to develop innovative treatments for genetic conditions through a model that emphasizes speed, precision, and scalability, addressing the needs of underserved patient populations.
Potential Positives
- BridgeBio Pharma will present additional data from the interim analysis of the ongoing Phase 3 clinical trial of BBP-418, indicating potential progress in developing a treatment for LGMD2I/R9.
- The late-breaking oral presentation at a prominent conference highlights BridgeBio's commitment to transparency and scientific engagement, potentially enhancing its reputation within the biopharmaceutical community.
- The involvement of academic collaborators from Yale School of Medicine in the presentations demonstrates strong partnerships in research and development, which can boost credibility and innovation.
Potential Negatives
- The press release indicates that the results of the interim analysis of the FORTIFY study will only be presented at a conference, which may suggest that the company is unable to release conclusive findings publicly at this stage, potentially raising concerns about the trial's progress or efficacy.
- The focus on presenting data at a conference rather than through a press release could indicate a lack of confidence in the data, as it may be seen as less accessible and less impactful than traditional announcements.
FAQ
What is the FORTIFY clinical trial?
The FORTIFY clinical trial is a Phase 3 study evaluating the efficacy of BBP-418 for treating LGMD2I/R9.
When will the interim analysis data be presented?
The interim analysis data will be presented during the late-breaking oral session on March 11, 2026, at 2:00 pm ET.
Who will present the interim analysis results?
Katherine Mathews, M.D., from the University of Iowa, will present the interim analysis results of the FORTIFY study.
What other presentations will BridgeBio feature?
BridgeBio will feature an oral presentation and four posters on BBP-418 and LGMD2I/R9 at the conference.
What is BridgeBio Pharma's mission?
BridgeBio Pharma aims to develop transformative medicines for genetic conditions, focusing on underserved patient populations.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 96 times in the past 6 months. Of those trades, 0 have been purchases and 96 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 72 sales selling 564,220 shares for an estimated $37,207,542.
- FRANK MCCORMICK has made 0 purchases and 7 sales selling 274,000 shares for an estimated $17,246,736.
- ANDREW LO has made 0 purchases and 4 sales selling 95,599 shares for an estimated $6,319,662.
- RONALD J DANIELS sold 61,031 shares for an estimated $3,888,999
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 4 sales selling 30,534 shares for an estimated $2,141,551.
- HANNAH VALANTINE sold 25,484 shares for an estimated $1,683,727
- RANDAL W. SCOTT has made 0 purchases and 5 sales selling 20,000 shares for an estimated $1,421,021.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,510 shares for an estimated $186,418.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BBIO Congressional Stock Trading
Members of Congress have traded $BBIO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 09/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$BBIO Hedge Fund Activity
We have seen 241 institutional investors add shares of $BBIO stock to their portfolio, and 223 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,261,181 shares (+144.2%) to their portfolio in Q4 2025, for an estimated $172,957,734
- JANUS HENDERSON GROUP PLC added 2,259,378 shares (+25.8%) to their portfolio in Q4 2025, for an estimated $172,819,823
- MACQUARIE GROUP LTD removed 1,933,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $147,862,513
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,602,036 shares (-78.0%) from their portfolio in Q4 2025, for an estimated $122,539,733
- VIKING GLOBAL INVESTORS LP removed 1,583,915 shares (-9.9%) from their portfolio in Q4 2025, for an estimated $121,153,658
- WELLINGTON MANAGEMENT GROUP LLP added 1,329,537 shares (+130.4%) to their portfolio in Q4 2025, for an estimated $101,696,285
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,051,679 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $80,442,926
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 01/28/2026
- Truist Securities issued a "Buy" rating on 01/08/2026
- Morgan Stanley issued a "Overweight" rating on 01/06/2026
- JP Morgan issued a "Overweight" rating on 11/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
- Goldman Sachs issued a "Buy" rating on 10/31/2025
- Raymond James issued a "Outperform" rating on 10/30/2025
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
$BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 16 analysts offer price targets for $BBIO in the last 6 months, with a median target of $95.0.
Here are some recent targets:
- Sean Laaman from Morgan Stanley set a target price of $98.0 on 02/25/2026
- Cory Kasimov from Evercore ISI Group set a target price of $125.0 on 02/25/2026
- Danielle Brill from Truist Securities set a target price of $95.0 on 02/25/2026
- Trevor Allred from Oppenheimer set a target price of $81.0 on 02/25/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $100.0 on 02/17/2026
- Derek Archila from Wells Fargo set a target price of $98.0 on 02/13/2026
- Eliana Merle from Barclays set a target price of $80.0 on 01/28/2026
Full Release
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio’s academic collaborators at Yale School of Medicine, along with four posters, will highlight advances in the understanding of BBP-418 and LGMD2I/R9.
Late-Breaking Oral Presentation:
Interim Analysis from Ongoing Phase 3 FORTIFY Study of BBP-418 for Patients with LGMD2I/R9 Meets Efficacy Endpoints
Presenter:
Katherine Mathews, M.D., Professor of Pediatrics and Neurology at the University of Iowa’s Roy J. and Lucille A. Carver College of Medicine
Date:
Wednesday, March 11 at 2:00 pm ET
Oral Presentation:
A High-Throughput Assay for Measuring Ribitol Response Across
FKRP
Variants
Presenter:
Yujiao Yang, Ph.D., Postdoctoral Associate in the Laboratory of Monkol Lek at Yale School of Medicine
Date:
Wednesday, March 11 at 11:30 am ET
Posters:
Systematic Literature Review of Clinical Outcomes and Disease Burden in LGMD2I/R9
Date:
Tuesday, March 10
Real-World Insights into LGMD, Including Subtype 2I/R9: Treatment Patterns, Health Care Resource Utilization, and Costs
Date:
Tuesday, March 10
Long-Term Survival, Quality-Adjusted Life-Years, and Economic Burden in LGMD2I/R9: A Health Outcomes Model
Date:
Tuesday, March 10
The Journey of BBP-418: From LGMD2I/R9 Disease Pathophysiology to Registrational Clinical Trials
Date:
Tuesday, March 10
About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on
LinkedIn
,
X
,
Facebook
,
Instagram
,
YouTube
, and
TikTok
.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
[email protected]
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]
